|
MONDAY, SEPTEMBER 23, 2002
| 13:00-14:40 |
Plenary Session 1:
Opening Ceremony |
|
- |
Official Opening/ Opening
Address - H.M. Pinedo, Amsterdam, NL |
|
- |
Presentation 'NDDO Honorary Award'
- C.K. van Kalken, Amsterdam, NL |
|
- |
KEYNOTE LECTURE: Signal
transduction in the Erb family of receptors - J.
Mendelsohn, Houston, TX |
|
- |
KEYNOTE LECTURE: Tyrosine kinases -
A. Ullrich, Munich, D |
|
14:40-15:00 Coffee break
| 15:00-17:15 |
Plenary Session 2.
STMs: Clinical and translational research (1) |
|
- |
Her-2 receptor/Herceptin -
J. Baselga, Barcelona, E |
|
- |
Small-molecule EGFR tyrosine kinase
inhibitors - G. Giaccone, Amsterdam, NL |
|
- |
Hsp90 inhibitors - P. Workman,
Sutton, UK |
|
- |
Inhibitors of MAP kinases -
A.A. Adjei, Rochester MN |
|
17:15-18:15 Welcome Reception
TUESDAY, SEPTEMBER 24, 2002
| 08:00-10:05 |
Plenary Session 3:
Anti-angiogenic approaches |
|
- |
Small-molecule angiogenesis inhibitors
- L.K. Shawver, San Francisco, CA |
|
- |
Endostatin / angiostatin -
J. Folkman, Boston, MA |
|
- |
Molecular imaging of anti-angiogenic
agents - G. Jayson, Manchester, UK |
|
- |
Surrogate markers in anti-angiogenesis
trials - R. Herbst, Houston, TX |
|
10:05-10:30 Coffee Break
| 10:30-12:30 |
Plenary Session 4:
Proffered Papers |
| |
Oral presentation of papers
selected from submitted abstracts |
|
12:30-15:00 Poster Sessions / Lunch
(all posters on display September 24-25)
| 15:00-17:05 |
Plenary Session 5.
STMs: Clinical and translational research (2) |
|
- |
Inhibitors of PI3 kinase -
G.B. Mills, Houston, TX |
|
- |
Proteasome inhibitors -
J. Adams, Cambridge, MA |
|
- |
Farnesylation inhibitors -
J.H.M. Schellens, Amsterdam, NL |
|
- |
STI-571: recent
developments - S.L. Silberman, East Hanover, NJ |
|
- |
STI-571
in GIST - J. Verweij, Rotterdam, NL |
|
WEDNESDAY, SEPTEMBER 25, 2002
| 08:00-10:05 |
Plenary Session 6.
STMs: Clinical and translational research (3) |
|
- |
mTOR / CCI-779 / rapamycin -
E.K. Rowinsky, San Antonio, TX |
|
- |
Molecular targets for prevention
of colorectal cancer: Erb-B, COX-2 & PPARs -
R.N. Dubois, Nashville, TN |
|
- |
Cyclin-dependent kinases -
A. Senderowicz, Bethesda, MD |
|
- |
Targeting FLT3 as a novel, specific
therapy for AML - D. Small, Baltimore, MD |
|
- |
The
Wnt cascade as a cause
of colon cancer - H. Clevers, Utrecht, NL |
10:05-10:30 Coffee Break
|
| 10:30-12:45
|
Plenary Session
7: Novel STMs in (pre)clinical
development |
|
- |
Oral presentation of
profiles of new agents in development (topics and
speakers to be announced) |
|
|
| 12:45-13:15 |
Poster Review - S.G. Eckhardt, Denver, CO |
|
|
| 13:15-14:30 |
Plenary Session 8:
Future directions (1) |
|
- |
Inhibition of multiple signal
transduction/ cell cycle pathways - S. Grant, Richmond,
VA |
|
- |
Modulation of death receptor pathways
- E.G.E. de Vries, Groningen, NL |
|
- |
Identification of molecular targets
using micro-arrays - A. Kallioniemi, Bethesda, MD |
|
14:30-14:55 Coffee Break
| 14:55-16:35 |
Plenary session 9:
Future directions (2) |
| 14:50-15:20 |
New treatment paradigms
t.b.a. |
| 15:20-15:45 |
EGFR signalling in cancer:
Prognostic and therapeutic implications R.I. Nicholson,
Cardiff, UK |
| 15:45-16:10 |
Clinical and surrogate
endpoints R. Pazdur, FDA, Rockville, MD |
| 16:10-16:35 |
Development of STM inhibitors
in oncology: an industry point of view G. Blackledge,
Alderley Park, UK |
16:35-16:45 Closing remarks
|
16:45-17:45 Farewell Drinks
|
